心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：下班时间的院内心脏停搏存活率明显低于工作时间

2018-01-31 MedSci MedSci原创

心血管心脏停搏
关注

医院内心脏停搏（IHCA）的存活率在晚上和周末（下班时间）要低于工作时间，尽管近年来的IHCA存活率明显上升，但是在下班时间和工作时间上的差异是否发生变化尚属未知。本研究的目的旨在评估IHCA在下班时间和工作时间存活率差异的变化趋势。本研究纳入了2000-2014年470家美国医院的151071名成年住院病人，通过多变量回归分析，评估IHCA存活率在工作时间（周一到周五的7：00am-10：59p

医院内心脏停搏（IHCA）的存活率在晚上和周末（下班时间）要低于工作时间，尽管近年来的IHCA存活率明显上升，但是在下班时间和工作时间上的差异是否发生变化尚属未知。本研究的目的旨在评估IHCA在下班时间和工作时间存活率差异的变化趋势。本研究纳入了2000-2014年470家美国医院的151071名成年住院病人，通过多变量回归分析，评估IHCA存活率在工作时间（周一到周五的7：00am-10：59pm）和下班时间（周一到周五的11：00 PM-6：59 AM和周末全天）差异的变化。分析结果显示，在151071名参与者中，有79091名（52.4%）患者在下班时间出现心脏停搏，存活率在两组患者之间均随着时间的推移而增高，然而，存活率在两组之间的差异没有明显的变化（绝对值：p=0.75；相对值：p=0.059）。此外，复苏成功率虽然随着时间的推移而增高，但两组之间的差异仍没有明显改变。研究结果显示，尽管院内心脏停搏存活率逐年升高，但是下班时间的存活率依旧低于工作时间。原始出处：Uchenna R et al.Trends in Survival After In-Hospital Cardi

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1715903, encodeId=51fc1e159030f, content=<a href='/topic/show?id=6e095142ee3' target=_blank style='color:#2F92EE;'>#心脏停搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51427, encryptionId=6e095142ee3, topicName=心脏停搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91132095598, createdName=klivis, createdTime=Thu Dec 20 06:20:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862916, encodeId=d6ea1862916f7, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Feb 21 03:20:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853922, encodeId=5b2d18539220d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Aug 17 12:20:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325689, encodeId=bb6c132568969, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Feb 02 06:20:00 CST 2018, time=2018-02-02, status=1, ipAttribution=)]
    2018-12-20 klivis

    #心脏停搏#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1715903, encodeId=51fc1e159030f, content=<a href='/topic/show?id=6e095142ee3' target=_blank style='color:#2F92EE;'>#心脏停搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51427, encryptionId=6e095142ee3, topicName=心脏停搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91132095598, createdName=klivis, createdTime=Thu Dec 20 06:20:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862916, encodeId=d6ea1862916f7, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Feb 21 03:20:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853922, encodeId=5b2d18539220d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Aug 17 12:20:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325689, encodeId=bb6c132568969, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Feb 02 06:20:00 CST 2018, time=2018-02-02, status=1, ipAttribution=)]
    2018-02-21 daviiliu

    #存活率#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1715903, encodeId=51fc1e159030f, content=<a href='/topic/show?id=6e095142ee3' target=_blank style='color:#2F92EE;'>#心脏停搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51427, encryptionId=6e095142ee3, topicName=心脏停搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91132095598, createdName=klivis, createdTime=Thu Dec 20 06:20:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862916, encodeId=d6ea1862916f7, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Feb 21 03:20:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853922, encodeId=5b2d18539220d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Aug 17 12:20:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325689, encodeId=bb6c132568969, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Feb 02 06:20:00 CST 2018, time=2018-02-02, status=1, ipAttribution=)]
    2018-08-17 hbwxf

    #JACC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1715903, encodeId=51fc1e159030f, content=<a href='/topic/show?id=6e095142ee3' target=_blank style='color:#2F92EE;'>#心脏停搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51427, encryptionId=6e095142ee3, topicName=心脏停搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91132095598, createdName=klivis, createdTime=Thu Dec 20 06:20:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862916, encodeId=d6ea1862916f7, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Feb 21 03:20:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853922, encodeId=5b2d18539220d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Aug 17 12:20:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325689, encodeId=bb6c132568969, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Feb 02 06:20:00 CST 2018, time=2018-02-02, status=1, ipAttribution=)]
    2018-02-02 12498568m50暂无昵称

    #ACC#

    0

相关资讯

JACC：大部分年轻心梗患者没有达到接受他汀类药物治疗的标准

尽管重视对心梗的预防，然而心梗在年轻的成年人中的发病率仍较高。本研究纳入的患者信息来自YOUNG-MI注册数据库，纳入了年龄≤50岁的心梗患者，并有对应的内科专家对心梗进行诊断和分型，通过混合队列风险方程评估心梗前和心梗发生中动脉粥样硬化性心血管疾病的风险。最终，有1685名患者符合入选标准，有210名患者在心梗发生前已经接受了他汀类药物治疗，被排除在外。在剩下的1475名患者中，平均年龄为45岁

JACC：药物治疗左束支传导阻滞预后不理想

左束支传导阻滞（LBBB）的患者对心脏再同步治疗（CRT）的反应较好，左室射血分数（LVEF）也有所提高。对于LVEF降低的LBBB患者，药物治疗（GDMT）而非CRT是一线治疗方法，然而，这类患者对GDMT的反应性如何尚属未知。本研究纳入了杜克心超实验室的数据库，入选了超声心动图诊断基线LVEF≤35%并且之后的3-6个月对LVEF进行了随访的患者。本研究排除了有严重瓣膜疾病、有植入性装置和心脏

JACC：指南联合生物标志物治疗心衰效率更佳

心衰指南推荐滴定法对血管紧张素转化酶抑制剂（ACEI）、血管紧张素受体阻滞剂（ARBs）、β受体阻滞剂和盐皮质激素受体抑制剂（MRAs）进行定量使用，然而实际情况很多均达不到要求。其实，滴定法定量并非对每个病人都是必要的。本研究的目的旨在通过血清标志物的方法来区分哪些患者需要用滴定法来进行心衰药物定量。本研究纳入了BIOSTAT-CHF临床试验中的2516名心衰患者，这些患者根据治疗情况分成了三组

Circulation： 心血管第一期刊：生酮饮食或又有新功能！科学家发现它可以改善心肌代谢，显著延缓心衰进展：科学大发现

近年来，生酮饮食在各大媒体上可谓是红到发紫。每隔一段时间，就会有关于生酮饮食的报道出来。当然，这种事情不能怪媒体跟风，只能怪生酮饮食功能的确太多了。

JAHA：血红蛋白浓度与心血管和全因死亡率的关系！

由此可见，低水平或高水平血红蛋白浓度与心血管和全因死亡率升高有关。将血红蛋白浓度维持在正常范围内与全因死亡率降低相关。

ISC2018：医学卒中急救奖获得者介绍运筹学和数据科学在心血管病中的应用

美国北卡罗莱纳大学荣获ISC 2018医学卒中急救奖在会上发表题为“采用离散事件仿真评估基于严重程度的EMS卒中分类转运流程对患者结局及分流的区域特异性影响”的精彩演讲，并接受了采访。